Literature DB >> 27989503

A Purinergic Trail for Metastases.

Davide Ferrari1, Fabio Malavasi2, Luca Antonioli3.   

Abstract

Nucleotides and nucleosides have emerged as important modulators of tumor biology. Recently acquired evidence shows that, when these molecules are released by cancer cells or surrounding tissues, they act as potent prometastatic factors, favoring tumor cell migration and tissue colonization. Therefore, nucleotides and nucleosides should be considered as a new class of prometastatic factors. In this review, we focus on the prometastatic roles of nucleotides and discuss future applications of purinergic signaling modulation in view of antimetastatic therapies.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  P1 receptors; P2 receptors; chemotaxis; extracellular nucleotides; tumor

Mesh:

Substances:

Year:  2016        PMID: 27989503     DOI: 10.1016/j.tips.2016.11.010

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  14 in total

1.  AMP hydrolysis reduction in blood plasma of breast cancer elderly patients after different treatments.

Authors:  Fernanda Valente Gheler; Angélica Regina Cappellari; Daiana Renck; Julia Brandt de Souza; Renan Oliveira de Melo; Barbara Zanesco Moehlecke; Carolina Aiko Moriguchi; Paula Engroff; Ana Paula Franco Lambert; Liliana Rockenbach; Fernanda Bueno Morrone
Journal:  Mol Cell Biochem       Date:  2021-06-05       Impact factor: 3.396

Review 2.  Purinergic drug targets for gastrointestinal disorders.

Authors:  Geoffrey Burnstock; Kenneth A Jacobson; Fievos L Christofi
Journal:  Curr Opin Pharmacol       Date:  2017-11-14       Impact factor: 5.547

Review 3.  Extracellular ATP and Macropinocytosis: Their Interactive and Mutually Supportive Roles in Cell Growth, Drug Resistance, and EMT in Cancer.

Authors:  Maria Evers; Jingwen Song; Xiaozhuo Chen
Journal:  Subcell Biochem       Date:  2022

Review 4.  Purinergic signaling and tumor microenvironment in cervical Cancer.

Authors:  Marta Schmidt Pfaffenzeller; Maria Luiza Mukai Franciosi; Andréia Machado Cardoso
Journal:  Purinergic Signal       Date:  2020-03-13       Impact factor: 3.765

Review 5.  P2X7 receptor: a critical regulator and potential target for breast cancer.

Authors:  Xiaodi Zhu; Qianqian Li; Wei Song; Xiaoxiang Peng; Ronglan Zhao
Journal:  J Mol Med (Berl)       Date:  2021-01-23       Impact factor: 4.599

6.  Cytokine-Induced Killer Cells Express CD39, CD38, CD203a, CD73 Ectoenzymes and P1 Adenosinergic Receptors.

Authors:  Alberto L Horenstein; Antonella Chillemi; Roberta Zini; Valeria Quarona; Nicoletta Bianchi; Rossella Manfredini; Roberto Gambari; Fabio Malavasi; Davide Ferrari
Journal:  Front Pharmacol       Date:  2018-04-20       Impact factor: 5.810

Review 7.  The potential of P2X7 receptors as a therapeutic target, including inflammation and tumour progression.

Authors:  Geoffrey Burnstock; Gillian E Knight
Journal:  Purinergic Signal       Date:  2017-11-21       Impact factor: 3.765

Review 8.  Small Molecules Enhance Scaffold-Based Bone Grafts via Purinergic Receptor Signaling in Stem Cells.

Authors:  Patrick Frank Ottensmeyer; Markus Witzler; Margit Schulze; Edda Tobiasch
Journal:  Int J Mol Sci       Date:  2018-11-14       Impact factor: 5.923

Review 9.  Structural and Functional Basis for Understanding the Biological Significance of P2X7 Receptor.

Authors:  María Ángeles Martínez-Cuesta; María Amparo Blanch-Ruiz; Raquel Ortega-Luna; Ainhoa Sánchez-López; Ángeles Álvarez
Journal:  Int J Mol Sci       Date:  2020-11-10       Impact factor: 5.923

Review 10.  Targeting the purinergic pathway in breast cancer and its therapeutic applications.

Authors:  Julia Beatrice de Araújo; Vanessa Vitória Kerkhoff; Sarah Franco Vieira de Oliveira Maciel; Débora Tavares de Resende E Silva
Journal:  Purinergic Signal       Date:  2021-02-12       Impact factor: 3.765

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.